Table 1 Baseline characteristics of HIV patients who initiated ART between 2010 and 2018 in Guangxi, China
Variable | Total | % | HIV only | % | HIV-HBV co-infection | % | HIV-HCV co-infection | % | HIV-HBV-HCV Triple infection | % |
|---|---|---|---|---|---|---|---|---|---|---|
Total | 58,239 | 100.0 | 46,847 | 100 | 6,707 | 100.0 | 3,828 | 100.0 | 857 | 100.0 |
Age, years | ||||||||||
18–50 | 34,424 | 59.1 | 25,731 | 54.9 | 4,504 | 67.2 | 3,404 | 88.9 | 785 | 91.6 |
≥ 50 | 23,815 | 40.9 | 21,116 | 45.1 | 2,203 | 32.8 | 424 | 11.1 | 72 | 8.4 |
Sex | ||||||||||
Male | 39,754 | 68.3 | 31,097 | 66.4 | 4,798 | 71.5 | 3,110 | 81.2 | 749 | 87.4 |
Female | 18,485 | 31.7 | 15,750 | 33.6 | 1,909 | 28.5 | 718 | 18.8 | 108 | 12.6 |
Marital status | ||||||||||
Married | 37,104 | 63.7 | 30,197 | 64.5 | 4,306 | 64.2 | 2,136 | 55.8 | 465 | 54.3 |
Other | 21,135 | 36.3 | 16,650 | 35.5 | 2,401 | 35.8 | 1,692 | 44.2 | 392 | 45.7 |
Route of HIV transmission | ||||||||||
Heterosexual intercourse | 50,836 | 87.3 | 42,911 | 91.6 | 6,118 | 91.2 | 1,480 | 38.7 | 327 | 38.2 |
Homosexual intercourse | 3,455 | 5.9 | 534 | 1.1 | 152 | 2.3 | 2,257 | 59.0 | 512 | 59.7 |
Intravenous drug use | 2,827 | 4.9 | 2,488 | 5.3 | 297 | 4.4 | 36 | 0.9 | 6 | 0.7 |
Other | 1,121 | 1.9 | 914 | 2.0 | 140 | 2.1 | 55 | 1.4 | 12 | 1.4 |
CD4 count before ART, cells/mm3 | ||||||||||
≤ 350 | 34,837 | 59.8 | 28,133 | 60.1 | 3,853 | 57.4 | 2,345 | 61.3 | 506 | 59.0 |
> 350 | 23,402 | 40.2 | 18,714 | 39.9 | 2,854 | 42.6 | 1,483 | 38.7 | 351 | 41.0 |
WHO clinical stage before ART | 47,524 | 81.6 | 38,079 | 81.3 | 5,513 | 82.2 | 3,187 | 83.3 | 745 | 86.9 |
I/II | 7,268 | 12.5 | 5,937 | 12.7 | 807 | 12.0 | 443 | 11.6 | 81 | 9.5 |
III/IV | 3,447 | 5.9 | 2,831 | 6.0 | 387 | 5.8 | 198 | 5.2 | 31 | 3.6 |
Initial first-line ART regimen | ||||||||||
ART containing D4T | 4,966 | 8.5 | 4,011 | 8.6 | 412 | 6.1 | 430 | 11.2 | 113 | 13.2 |
ART containing AZT | 19,621 | 33.7 | 17,208 | 36.7 | 1,027 | 15.3 | 1,176 | 30.7 | 210 | 24.5 |
ART containing TDF | 27,246 | 46.8 | 20,270 | 43.3 | 4,634 | 69.1 | 1,881 | 49.1 | 461 | 53.8 |
ART containing LPV/r | 5,863 | 10.1 | 4,862 | 10.4 | 610 | 9.1 | 319 | 8.3 | 72 | 8.4 |
Other | 543 | 0.9 | 496 | 1.1 | 24 | 0.4 | 22 | 0.6 | 1 | 0.1 |
Current ART regimen | ||||||||||
First-line ART | 45,854 | 78.7 | 36,743 | 78.4 | 5,311 | 79.2 | 3,107 | 81.2 | 693 | 80.9 |
Second-line ART | 12,385 | 21.3 | 10,104 | 21.6 | 1,396 | 20.8 | 721 | 18.8 | 164 | 19.1 |
Duration of TDF -containing regimens | ||||||||||
≤ 2 years | 33,115 | 56.9 | 27,865 | 59.5 | 2,740 | 40.9 | 2,088 | 54.5 | 422 | 49.2 |
> 2 years | 25,124 | 43.1 | 18,982 | 40.5 | 3,967 | 59.1 | 1,740 | 45.4 | 435 | 50.8 |
Calendar year of ART initiation | ||||||||||
2010 | 3,515 | 6.0 | 2,518 | 5.4 | 437 | 6.5 | 425 | 11.1 | 135 | 15.8 |
2011 | 4,982 | 8.6 | 3,839 | 8.2 | 604 | 9.0 | 414 | 10.8 | 125 | 14.6 |
2012 | 6,226 | 10.7 | 4,876 | 10.4 | 700 | 10.4 | 537 | 14.0 | 113 | 13.2 |
2013 | 6,384 | 11.0 | 5,057 | 10.8 | 738 | 11.0 | 487 | 12.7 | 102 | 11.9 |
2014 | 7,290 | 12.5 | 5,755 | 12.3 | 883 | 13.2 | 558 | 14.6 | 94 | 11.0 |
2015 | 8,016 | 13.8 | 6,524 | 13.9 | 954 | 14.2 | 450 | 11.8 | 88 | 10.3 |
2016 | 7,421 | 12.7 | 6,170 | 13.2 | 823 | 12.3 | 349 | 9.1 | 79 | 9.2 |
2017 | 7,164 | 12.3 | 5,954 | 12.7 | 830 | 12.4 | 315 | 8.2 | 65 | 7.6 |
2018 | 7,241 | 12.4 | 6,154 | 13.1 | 738 | 11.0 | 293 | 7.7 | 56 | 6.4 |